BACKGROUND: Previous studies have demonstrated therapeutic benefits of slow breathing (SLOWB) in chronic heart failure (HF) but its impact on cardiovascular reactivity in response to laboratory stressors remains unknown. METHODS: Using device-guided breathing this study explored the acute and long-term effects of SLOWB on hemodynamic responses to handgrip, mental and cold pressor tests, and health-related quality of life (QoL) in stable HF patients with reduced ejection fraction (HFrEF) who had received all available optimal drug and device therapies. Blood pressure (BP) and heart rate (HR) were measured in 21 patients with HFrEF (23.9 ± 5.9%) at rest, during laboratory stressors, before and after acute SLOWB, and 12 weeks after SLOWB home training (30 min daily). Health-related QoL (MacNew questionaries) was assessed before and 12 weeks after SLOWB home training. RESULTS: Resting BP significantly increased in response to three laboratory stressors. Pressor and cardiac changes during mental stress were greater than responses to the handgrip test (p < 0.05). Mental stress also produced a greater HR change than cold pressor test (p < 0.05). Both acute and long-term SLOWB significantly reduced BP and HR responses to mental stress (p < 0.05), but not to isometric and cold pressor tests. SLOWB improved scores of all domains of QoL (p < 0.05) at 12 weeks follow-up. CONCLUSIONS: These findings demonstrate that SLOWB reduces acute and chronic effects of cardiovascular reactivity to mental stress and improves various aspects of health-related QoL in patients with severe HFrEF. Whether stress reduction and psychological changes achieved with SLOWB may translate to improved outcomes in HFrEF warrants further exploration.
BACKGROUND: Previous studies have demonstrated therapeutic benefits of slow breathing (SLOWB) in chronic heart failure (HF) but its impact on cardiovascular reactivity in response to laboratory stressors remains unknown. METHODS: Using device-guided breathing this study explored the acute and long-term effects of SLOWB on hemodynamic responses to handgrip, mental and cold pressor tests, and health-related quality of life (QoL) in stable HF patients with reduced ejection fraction (HFrEF) who had received all available optimal drug and device therapies. Blood pressure (BP) and heart rate (HR) were measured in 21 patients with HFrEF (23.9 ± 5.9%) at rest, during laboratory stressors, before and after acute SLOWB, and 12 weeks after SLOWB home training (30 min daily). Health-related QoL (MacNew questionaries) was assessed before and 12 weeks after SLOWB home training. RESULTS: Resting BP significantly increased in response to three laboratory stressors. Pressor and cardiac changes during mental stress were greater than responses to the handgrip test (p < 0.05). Mental stress also produced a greater HR change than cold pressor test (p < 0.05). Both acute and long-term SLOWB significantly reduced BP and HR responses to mental stress (p < 0.05), but not to isometric and cold pressor tests. SLOWB improved scores of all domains of QoL (p < 0.05) at 12 weeks follow-up. CONCLUSIONS: These findings demonstrate that SLOWB reduces acute and chronic effects of cardiovascular reactivity to mental stress and improves various aspects of health-related QoL in patients with severe HFrEF. Whether stress reduction and psychological changes achieved with SLOWB may translate to improved outcomes in HFrEF warrants further exploration.
Entities:
Keywords:
health-related quality of life; heart failure with reduced ejection fraction; hemodynamics; laboratory stressors; slow breathing
Authors: Markku S Nieminen; Kenneth Dickstein; Cândida Fonseca; Jose Magaña Serrano; John Parissis; Francesco Fedele; Gerhard Wikström; Piergiuseppe Agostoni; Shaul Atar; Loant Baholli; Dulce Brito; Josep Comín Colet; István Édes; Juan E Gómez Mesa; Vojka Gorjup; Eduardo Herrera Garza; José R González Juanatey; Nenad Karanovic; Apostolos Karavidas; Igor Katsytadze; Matti Kivikko; Simon Matskeplishvili; Béla Merkely; Fabrizio Morandi; Angel Novoa; Fabrizio Oliva; Petr Ostadal; Antonio Pereira-Barretto; Piero Pollesello; Alain Rudiger; Robert H G Schwinger; Manfred Wieser; Igor Yavelov; Robert Zymliński Journal: Int J Cardiol Date: 2015-05-01 Impact factor: 4.164
Authors: Ana Cristina Perez-Moreno; Pardeep S Jhund; Michael R Macdonald; Mark C Petrie; John G F Cleland; Michael Böhm; Dirk J van Veldhuisen; Lars Gullestad; John Wikstrand; John Kjekshus; James D Lewsey; John J V McMurray Journal: JACC Heart Fail Date: 2014-04 Impact factor: 12.035
Authors: G Grassi; G Seravalle; B M Cattaneo; A Lanfranchi; S Vailati; C Giannattasio; A Del Bo; C Sala; G B Bolla; M Pozzi Journal: Circulation Date: 1995-12-01 Impact factor: 29.690
Authors: Kamila Lachowska; Jerzy Bellwon; Krzysztof Narkiewicz; Marcin Gruchała; Dagmara Hering Journal: Clin Res Cardiol Date: 2018-06-25 Impact factor: 5.460